Medsider: Learn from Medtech and Healthtech Founders and CEOs

In this episode of Medsider Radio, we sat down with Eugene Malinskiy, CEO and Co-founder of Lazurite.Eugene is a serial entrepreneur with expertise in the IT and medical fields. He also has hands-on experience as a medic and has worked in operating rooms throughout the country. He founded Lazurite, an innovative healthcare company focused on cutting-edge surgical and lighting technologies, in 2015. That same year, Eugene was selected as one of Forbes 30 Under 30 recipients in the manufacturing sector.In this discussion, Eugene shares how planning out every step of ArthroFree’s regulatory strategy helped streamline the FDA clearance process, the importance of preparing for failure and being ready to solve problems, and why entrepreneurs should seek out input from investors at every step of the process. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Eugene if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Cody Simmons, CEO of DermaSensor.Cody spent four years learning about business strategy and analytics at biotechnology giant Genentech before becoming CEO of DermaSensor in 2016, where he leads development and commercialization efforts for the company’s novel skin cancer detection tool. In 2018, he was included on the Forbes 30 Under 30 list in healthcare.In this discussion, Cody shares why he thinks companies need to focus on regulatory and reimbursement alignment from the very beginning, the importance of finding ally investors, and how to build trust with potential partners in your network.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Cody if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Sina Habibi, CEO of Cognetivity.Sina has a Ph.D. in engineering from the University of Cambridge, where he met his business partner Seyed-Mahdi Khaligh-Razavi. The two co-founded Cognetivity Neurosciences, which develops cognitive assessment tests for clinicians and patients to detect cognitive impairment, including dementia. In this discussion, Sina shares the importance of collaborating with regulators and end users, why he primarily focuses on the value of revenue generation versus cost savings, and the benefits of teaming up with an expert fundraiser. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Sina if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Olivier Delporte, CEO of Miracor Medical.Olivier has more than 20 years of sales, marketing, and general management experience, mostly in the medical device industry. In 2016, he became the CEO of Miracor Medical, a medical device company based in Belgium. Under Olivier’s guidance, the company is advancing its flagship PiCSO treatment for severe myocardial infarction. In this discussion, Olivier explains why he advocates for randomized clinical trials, how remote monitoring tools can make clinical trial programs more efficient, and why startups should increase their fundraising goals. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Olivier if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Laura Yecies, CEO of Bone Health Technologies.Laura is a Silicon Valley veteran with more than three decades of experience at major tech companies and startups. She’s always had an interest in improving people’s health and wellness and was drawn to medtech startup Bone Health Technologies, which is developing a vibration belt intended to prevent osteoporosis. In this discussion, Laura shares why you should look for investors who are passionate about your mission, how FDA clearance can boost consumer confidence in your technology, and why patients should be at the center of everything you do. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Laura if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Justin Zenanko and Greg Molnar, co-founders of SynerFuse. Justin is a Certified Public Accountant who previously led fundraising efforts at Recombinetics and Greg is the former Director of Neuromodulation Research at Medtronic. In 2018, they joined forces to build SynerFuse, a clinical-stage startup developing an innovative therapy to relieve chronic back pain.In this discussion, the two SynerFuse co-founders share their experience launching an innovative therapy to address chronic back pain, how they are navigating challenging regulatory waters, and why they chose to invest heavily in their own venture. Before we jump into the discussion, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Justin and Greg if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with David Neale, CEO and co-founder of Argá Medtech.David has three decades of experience bringing medical goods, services, and devices to bear across a range of sectors and in multiple countries. In 2020, he launched Argá Medtech, a multinational company focused on developing new, more efficient ways to treat atrial fibrillation. In this conversation, David explains how being a multinational company increased their chances of success, and why startups should incorporate economic outcomes into their clinical studies. Before we jump into the discussion, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with David if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Justin Barad, Co-Founder and CEO of Osso VR.Justin is an orthopedic surgeon with a passion for technology and a history of working in the video game industry. Using his experience and knowledge, he developed a virtual reality platform that can reform the way surgeons are trained and assessed. In this conversation, Justin explains how he avoids being pulled in multiple directions with his technology, why it’s important to let potential customers get hands-on with your platform, and why tech can and should be fun — even in healthcare.Before we jump into the discussion, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Justin if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with John Mastrototaro, CEO of Movano.John has more than 30 years’ worth of experience in the medical device industry and was part of the MiniMed team that helped develop the world’s first ambulatory continuous glucose monitoring system and sensor-augmented insulin pump. John is now CEO and Director of Movano, a health technology company that makes smart, personalized devices that can provide vital health information to users. In this conversation, we discuss how medtech companies can build a successful consumer-facing brand while developing products that meet the needs of payers and providers. Before we jump into the discussion, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with John if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Jim Biggins, Founder and CEO of Access Vascular.Before starting the company, Jim developed innovative products for companies like Boston Scientific, Ocular Therapeutix, and Medtronic. He then spent 18 months shadowing clinicians in real-life medical settings, which led to the creation of Access Vascular's novel biomaterial for vascular access devices aimed at reducing common patient complications.In this conversation, Jim shares the importance of hearing directly from clinicians in the field, how to plan out a clinical research strategy, and the benefit of questioning assumptions when it comes to commercialization.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Jim if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Caroline Loew, President and CEO of Glympse Bio.Caroline has been with Glympse Bio since 2018. Prior to that, she held executive roles at Merck and Bristol Myers Squibb, where she oversaw R&D. Caroline earned her bachelor’s and doctoral degrees at Imperial College, London. In this discussion, Caroline shares her “early-and-often” approach to dealing with regulatory issues and outlines four things to consider ahead of conversations with potential investors. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Caroline if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Rosina Samadani, CEO of Oculogica.Rosina Samadani initially joined Oculogica in an advisory role, supporting her neurosurgeon sister’s plan to develop EyeBOX, a diagnostic medtech device for concussions. In 2015, Rosina transitioned into her current role as President and CEO of the company. With a doctorate in biomedical engineering from MIT, Rosina has been involved with multiple startups. She also serves as a judge for Stanford’s StartX Accelerator, and MIT’s $100K Entrepreneurship Competition. In this discussion, Rosina shares the importance of relationships in the regulatory and reimbursement processes, why first-time entrepreneurs shouldn’t be intimidated by complex procedures, and lessons learned from her experiences raising capital.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Rosina if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with John Murphy, President and CEO of Virtual Incision.With a background in life sciences, aerospace, private equity, and venture capital, John co-founded Virtual Incision in 2006. The company makes miniature, portable robots that can be used to perform specific operations. The first iteration is designed for colon resections, with new variations planned for the future.In this discussion, John shares tips on how to raise funds as an early-stage medical device company, planning a regulatory pathway that complements your product roadmap, and how to follow a dual-track approach to exiting (warning: it’s a lot of work).Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with John if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Robert Fenton, the founder and CEO of Qualio, a cloud-based all-in-one quality management system (QMS) for life sciences companies. Prior to founding Qualio in 2012, Robert studied pharmacy for five years at the University College Cork, practiced as a community pharmacist, and spent time in quality and R&D roles at global pharmaceutical companies including Pfizer and LEO Pharma. Robert made the move to San Francisco in 2016 after bootstrapping Qualio in his home country of Ireland. In this episode of Medsider, Robert shares his predictions for the life sciences industry in 2022. He also discusses how Qualio can support (and not hinder) medtech and healthtech companies as they move through the complex process of taking a product from conception to the market. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Robert if you'd rather read it instead.

In this episode of Medsider Radio, we’re sitting down with Holly Rockweiler, co-founder and CEO of Madorra.Holly spent the early part of her career working as a research scientist for Boston Scientific. In 2013, she took a fellowship at Stanford University’s Byers Center for Biodesign, where she met her future business partner, Ryan Krone. Through the fellowship, Holly and Ryan developed Madorra, a non-hormonal medical device that treats vaginal dryness. As co-founder and CEO of Madorra, Holly’s on a mission to improve women’s health. In this episode of Medsider, Holly discusses the importance of listening to your patients when developing medtech solutions, and why having a cause can be a valuable motivator. She also shares her most valuable learnings from participating in Stanford's Biodesign program. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Holly if you'd rather read it instead.

In this episode of Medsider Radio, we’re sitting down with Robert Kline, the Chairman of ThermoTek.Robert left big pharma to start Medivance in 1998, which he later sold for $260 million in 2011. His next venture, ViroCyt, a spin-off from the University of Colorado, sold in 2016 for $16 million. Robert then joined startup Bolder Surgical in 2017, pivoted it, and sold the company in 2021 for $160 million. He’s now Chairman of ThermoTek.In this episode of Medsider, Robert shares the lessons he learned from leading three medtech companies through successful acquisitions: never underestimate the importance and difficulty of fundraising, don’t assume everyone has the problem you want to solve, and don’t build your company around an exit. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Robert if you'd rather read it instead.

In this episode of Medsider Radio, we’re sitting down with Kevin Goodwin, the CEO and founder of EchoNous. Kevin has already been part of a medical first. In 1998, he founded Sonosite, which released the first point-of-care ultrasound device (PoCUS) the following year. It was a classic startup story: Sonosite hit NASDAQ immediately after launching, with no product, no approval from the Food and Drug Administration (FDA), and no revenue. Sonosite was acquired by Fujifilm in 2012, and Kevin left the company in 2014. In 2015, Kevin co-founded EchoNous, to make a handheld PoCUS device that cost significantly less than the models used as the standard in hospitals. Even more ambitious, it would use AI and ML to not only deliver more accurate results, but to improve the detail and accuracy of those results over time. The company’s AI-powered Kosmos platform was approved by the FDA in 2020. In this episode of Medsider, Kevin explains the pros and cons of public versus private investors, what happens when a competitor with an inferior product dominates the headlines, and why the toughest potential customers are the ones you should try to win over first.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Kevin if you'd rather read it instead.

In this episode of Medsider Radio, we’re sitting down with Marcus Gerhardt, who has started multiple companies, including an eCommerce platform and international consulting firm. In 2008, he co-founded Blackrock Neurotech, a pioneer in brain-computer interface (BCI) technology, and the world’s leading collaborative partner for developing approved medical devices at scale for neurological therapies. He currently serves as CEO and is on the company’s board.In this episode of Medsider, Marcus explains why Blackrock’s business model works for medtech companies, how the approach gave the company an “in” with the neuroscience research community, and why medical device companies need to work with — and not against — regulatory bodies like the Food and Drug Administration (FDA). Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Marcus if you'd rather read it instead.

In this episode of Medsider Radio, we’re sitting down with Patricia Zilliox, who has spent her entire career working in ophthalmology, including 30 years at American-Swiss medical company Alcon. In 2017, Patricia became CEO of Eyevensys, a biotech company in the clinical stage of making a drug delivery system to fight various eye diseases. In this interview, Patricia gives advice for navigating the complicated world of regulatory affairs, the dos and don’ts of planning clinical trials, and why raising capital is the most frustrating part of her job.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Patricia if you'd rather read it instead.

In this episode of Medsider Radio, we caught up with the HealthQuest Capital Founder, Garheng Kong, who worked at GlaxoSmithKline, McKinsey, and TherOx before transitioning into healthcare investing with Intersouth Partners and Sofinnova. Garheng’s resume is broad and deep. He has earned numerous degrees from two of the nation’s most prestigious universities — Stanford and Duke — and funded an equally impressive collection of healthcare companies throughout his career. Garheng and his team see up to 1,000 investment opportunities in any given year. The experience has taught him how to assess which ones are right for the firm, and which he can afford to let go of. In this interview, Garheng shares keen insights for startups and innovators preparing to pursue funding, along with observations about how the healthcare industry has shifted thanks to the global COVID-19 pandemic. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Garheng if you'd instead read it.

In this episode of Medsider Radio, we’re talking with Lightpoint Medical CEO Graeme Smith, a medtech veteran with over 32 years of experience in the industry. After joining Lightpoint earlier this year, Graeme was charged with commercializing its drop-in gamma probe, SENSEI, a revolutionary tool used in surgeries to non-invasively identify the presence of cancer. In this Medsider interview, Graeme shares his tried and true strategies for successful commercial launches and how to introduce products using a global distribution model. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Graeme if you'd rather read it instead.

In this episode of Medsider Radio, we caught up with Steve Anderson, CEO of Preceptis Medical, and a serial medical device entrepreneur. While serving as CEO of Acorn Cardiovascular, he and a neighbor came up with the idea of creating a device that could help doctors insert a tube in children’s ears in the doctor’s office instead of the operating room. They ended up starting Preceptis Medical in 2011, and in 2020, their Hummingbird device received clearance from the FDA.In this discussion, Steve explains why your value proposition needs to be front of mind from the start, why having someone who’s been there and done it before can help you navigate the process of getting to market and writing a study protocol that shows regulators exactly what they need to see. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Steve if you'd rather read it instead.

In this episode of Medsider Radio, we caught up with chemical engineer and serial entrepreneur Peter Vranes, the Co-Founder and CEO of Nutromics, an Australian medtech company that is developing a digitally connected wearable patch to track molecular targets.Previously, Peter founded Biocore Technologies, which developed natural cosmeceutical skincare brands with distribution in 1,500 retailers throughout Australia. He had a successful exit in 2013.In this fun discussion, Peter explains how he learned to embrace publicity as a necessary part of doing business, why getting your device approved goes beyond government regulatory bodies and the reason he never stops raising money. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Peter if you'd rather read it instead.

In this episode of Medsider Radio, we’re talking with ReShape Lifesciences CEO Bart Bandy, who started out selling medical equipment door-to-door, then landed a spot in the first sales class for Ethicon Endo-Surgery. He ran the company’s global sales and managed the San Francisco division, before becoming the Group Marketing Manager of Karl Storz Endoscopy.In 1999, Bart was recruited to become COO of laparoscopic weight loss startup Inamed. He helped manage the company’s $3.5 billion acquisition by Allergan in 2006. Then in 2019, he became CEO and President of ReShape, which had just acquired the Lap-Band, previously owned by Inamed.In this discussion, Bart explains how he writes and tests his presentations for maximum impact, the challenges and solutions of moving manufacturing from Costa Rica to the U.S., and why he wanted to add telemedicine to ReShape Lifesciences without moving away from the brand’s core mission.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Bart if you'd rather read it instead.

In this episode of Medsider Radio, we caught up with IONIQ Sciences CEO Jared Bauer, who has spent his career turning around struggling medtech companies. He acquired BurnFree Products in 2012, selling it four years later. In 2014, he became CEO of the mobile diagnostics system ApolloDx. Shortly after, he became CEO of the spin-off company Cibus Biotechnologies, which makes a handheld diagnostic system to test for infectious diseases. In this conversation, Jared explains the two key factors he looks at when determining whether a medical device company is worth trying to turn around, why finding investors who really care about your mission is a strategic benefit, and why he hopes that IONIQ’s devices will one day have a place in your medicine cabinet. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Jared if you'd rather read it instead.

In this episode of Medsider Radio, we caught up with health economist, Nic Anderson, who spent seven years at Intermountain Healthcare on the payer side. He learned first-hand what evidence insurers need to convince them to cover a new medical device or healthcare technology. After co-founding a biotech company, Nic turned his experience as a payer into an in-demand consultancy. He’s also served on payer advisory boards and was an expert in residence at a digital health accelerator in Dubai. He now works as a health economist for Boston Scientific.In this conversation, Nic explains why medtech companies, in particular, need to win over insurance payers, how investing early in a health economics and market access (HEMA) team will help you do that, and how to write a dossier a payer won’t want to throw out the window.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Nic if you'd rather read it instead.

In this episode of Medsider Radio, we caught up with Giovanni Lauricella and Aaron Green to discuss all things related to fundraising for early-stage medical device start-ups. In this interview, we learn about the ins and outs of raising medtech capital, what investors want to see in a medical device start-up, and best practices for pitching potential partners. But first, here’s a bit more about their backgrounds:Giovanni Lauricella holds a Bachelor’s in Finance, a Master’s in Regulatory Affairs in Medical Devices, Biologics, and Pharmaceuticals, a Harvard University Certificate for Advanced Negotiation Strategy, and a Università Bocconi Certificate for Private Equity and Venture Capital. He has more than a decade of experience partnering with startups, SMEs, boards of directors, and investors on structuring technical and commercial teams from the C-level to individual contributors. Giovanni and his team have hired more than 7,000 employees for over 500 startups in more than 40 countries and assisted in facilitating capital raises for startups that amount to more than $150 million.Aaron Green has a Ph.D. in computational chemistry from UCLA. In 2014, he became the first hire at Neural Analytics (now NovaSignal) where he held leadership roles spanning clinical, finance, sales, and marketing. Aaron currently runs U.S. operations for Labgnostic, a global interoperability platform for clinical laboratories. He co-founded MedTech Money with Giovanni Lauricella in 2020 and founded ExtractEx, a botanical extraction startup, in 2021. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Giovanni and Aaron if you'd rather read it instead.

In this episode of Medsider Radio, we’re talking with Dr. Asha Parekh, a biomedical engineer and the co-founder & CEO of FrontLine Medical Technologies, a Canadian medical device startup. FrontLine has developed a novel REBOA device that helps trauma patients survive in emergency situations. If you're not familiar, REBOA stands for Resuscitative Endovascular Balloon Occlusion of the Aorta.In this discussion with Asha, we learn about her medtech journey from early-stage device prototypes to raising venture capital to navigate the global regulatory landscape. But first, here’s a bit more on Asha’s background:Asha has a Ph.D. in biomedical engineering from Western University in Ontario. In 2015, she partnered with Dr. Adam Power, a practicing vascular surgeon, to co-found FrontLine, which makes the COBRA-OS device for trauma patients. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Asha if you'd rather read it instead.

In this episode of Medsider Radio, we're chatting with Mark Toland, a veteran medtech executive who is the CEO of MMI, a startup medical device company in the robotics space. MMI stands for Medical Micro Instruments, and it’s an Italian company that’s developing a surgical robotic system capable of performing microsurgery on capillaries, small vessels, and other parts of the body existing robotic technology can’t reach. We’re going to dig into the robotics arena and chat about things like growing medtech startups, raising venture capital, positioning for an acquisition, and keys to successful commercial launches. First, here’s a bit more on Mark's background: Before MMI, Mark was the CEO of Corindus, transforming the company into a leader in vascular robotics before it was acquired by Siemens for $1.1 billion in 2019. Prior to Corindus, Mark was at Boston Scientific for over 15 years, serving as Senior Vice President, where he built the company’s global solutions business and led all aspects of the U.S. commercial team’s cardiovascular businesses, representing approximately $4 billion in revenue. He also serves on the Board of Directors for Cardiologs, a cardiovascular AI company, and Amplitude Vascular Systems, an intravascular lithotripsy company. He also serves as a partner and EIR at Biostar Capital, a healthcare-focused venture capital firm. Mark got his bachelor’s in business from the University of Louisville. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Mark if you'd rather read it instead.

In this episode of Medsider Radio, we're catching up with Derek Herrera, who has an incredible story to share. He’s a decorated Marine veteran who’s turned a major combat injury into a mission to help other patients with spinal injuries. Derek is the founder of UroDev, originally Spinal Singularity, as well as Habit Camera, the first low-cost, wireless camera purpose-built for skin inspection and telehealth.UroDev is on the cusp of bringing its Intelliflow device to market, a product uniquely designed for spinal injury patients who have urology conditions like a neurogenic bladder that require extensive catheter use. Today, Derek and I are going to chat about his journey from the military to the medical device space and get into what he’s learned about becoming a first-time entrepreneur with a big idea but not a lot of funding or experience. First, here’s a bit more on Derek’s background: He graduated from the United States Naval Academy and served as a Marine Infantry and Special Operations Officer for over eight years. In 2014, he was medically retired due to combat injuries and left paralyzed from the waist down. Since this injury, Derek has earned an MBA from the UCLA Anderson School of Management and founded both UroDev and Habit Camera. He also serves as President of the Board for the Marine Raider Foundation. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Derek if you'd rather read it instead.

In this episode of Medsider Radio, we’re catching up with Bob Paulson, the CEO of VentureMed, a peripheral vascular medtech startup. Bob has over two decades of medical device executive experience, as the CEO of NxThera and Restore Medical, and in leadership roles at Endocardial Solutions, Advanced Bionics, and Medtronic. Bob’s excited multiple medtech startups, and today, he’s going to share his vast expertise, including capital fundraising tips, keys to early-stage medical device product development, and best practices when it comes to clinical evidence and insurance reimbursement. But first, here’s a bit more on Bob’s background:In addition to being CEO of VentureMed, he serves as a Director for Veran Medical Technologies and Spineology. Before he got started in medtech, he worked for General Mills, got an MBA from St. Thomas, and went to law school at Vanderbilt. Bob got involved with medical devices at Medtronic in the early 90s and later was CEO of NxThera, which commercialized benign prostate hyperplasia therapies before it was acquired by Boston Scientific. Bob is one of the most knowledgeable executives in the field, and I’m excited to get his take on the business landscape in today’s rapidly-changing healthcare environment. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Bob Paulson if you'd rather read it instead.

In this episode of Medsider Radio, we’re chatting with Dr. Scott Wolf, a prolific medical device entrepreneur and investor who founded Aerin Medical to bring non-surgical therapies to patients with common nasal airway problems. Prior to founding Aerin Medical, Scott started Zeltiq Aesthetics, the maker of CoolSculpting. His other startups include Endogastric Solutions and Cardiac Dimensions, and he was a partner at Prospect Venture Partners as well as VP at Frazier Healthcare Ventures, both leading life science venture capital firms. Scott received his M.D. from George Washington University and his B.A. from the University of Pennsylvania.You won’t find many people with more hands-on medtech experience than Dr. Scott Wolf, and today he’s going to share his expertise with the Medsider community. In this interview, we’ll discuss Aerin’s technology, break down the advantages of cash-pay versus insurance reimbursement, and get Scott’s advice for would-be founders hoping to turn a great idea into a real prototype.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Dr. Scott Wolf if you'd rather read it instead.

In this episode of Medsider Radio, we’re talking with Rohan Dixit, the Founder and CEO of Lief Therapeutics, which makes consumer- and clinical-grade wearable devices for mental health. Rohan is a neuroscientist who started his career as a researcher with Stanford and Harvard. Rohan founded BrainBot, his first company, at age 23. He’s been the CEO of Lief since 2015.Today, Rohan’s going to break down how Lief started, and we’ll get into product development, how he approaches clinical research, why they initially launched their device as an over-the-counter consumer product, and many other topics related to medtech startups. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Rohan Dixit if you'd rather read it instead.

In this episode of Medsider Radio, we’re talking with Nadim Yared, the CEO of CVRx, a pioneer in neuromodulation for cardiovascular diseases. Nadim has been CEO for 15 years and led CVRx through some major pivots and incredible successes. Today, we’re going to discuss his journey with the company, including Nadim’s expertise on clinical trial strategy, startup funding, and working with FDA & CMS. But first, here’s a bit more about Nadim Yared and his background: Nadim holds two graduate degrees, and started his career with GE. After getting his MBA at INSEAD, he went on to run several business units for GE, then spent four years as the head of Medtronic’s Surgical Navigation division. Nadim was then recruited to take the helm at CVRx in 2006, and has been CEO ever since. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Nadim Yared if you'd rather read it instead.

In this episode of Medsider Radio, we’re talking with the CEO of Lungpacer Medical, Doug Evans. Lungpacer is developing a novel therapeutic solution that preserves the strength of the diaphragm muscle for critically-ill patients on mechanical ventilation. Doug is also a board member of Intact Vascular, which was acquired by Philips, and the former COO of Kensey Nash. He’s a medtech veteran with decades of experience launching startups, developing products, working with payers & regulators, and commercializing novel technologies. Today, we’re going to discuss all these topics and hear more about Lungpacer’s impressive technology. But first, here’s a bit more about Doug Evans and his background: Doug started his career at GE in business development and later joined Kensey Nash when it was just a startup with fewer than ten employees. As COO, he led Kensey’s growth to over 400 employees, across the span of 20 years, before they were acquired by Royal DSM. After that, Doug began working with other startups like Intact Vascular and TELA Bio.Doug holds a master's degree in electrical engineering and photonics from Penn, as well as an MBA. He knows the medtech startup landscape better than just about anyone, and we’re grateful he’s sharing his perspective with the Medsider community. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from medtech experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit. In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Doug Evans if you'd rather read it instead.

We recently caught up with Renee Ryan, the CEO of Cala Health, a bioelectronic medicine company that’s focused on wearable neuromodulation therapies that deliver individualized peripheral nerve stimulation. Renee has 25 years of experience in healthcare as an executive and investor, and in this episode, she shares her expertise with the Medsider community. Renee will discuss some common mistakes that medtech startups make, and talk about what she looks for as an investor in early-stage companies. She shares tips on navigating the regulatory waters and obtaining insurance coverage & reimbursement. Renee also gives us some key learnings from her time at Johnson & Johnson, and talks about what’s new at Cala Health, including their recent FDA breakthrough device designation. But first, here’s a bit more on Renee’s background:She has 25 years of experience in the healthcare space. Previously, Renee led the medical technology investments for Johnson & Johnson Innovation on the West Coast and Asia Pacific for 8 years. While at J&J, she made over 15 new investments, including the Series A for Cala Health. Prior to her time at J&J, she was a healthcare investment banker at RW Baird, Jefferies, and Goldman Sachs. Renee has a great eye for innovation, and we’re excited to welcome her to Medsider today. Before we jump into the conversation, I wanted to mention a few things:First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.I’ve never tried this before, so let me know what you think!Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. Lastly, here's the link to the full interview if you'd rather read it instead.

We recently caught up with medtech start-up extraordinaire, Mike Wallace, who shares his insights and experiences with the Medsider community. Mike is the co-founder and CEO of DeVoro Medical, an early-stage medical device company focused on developing innovative devices for peripheral thrombectomy.Mike says the initial idea or concept for a medtech company is just 5% of the journey. Medsider is all about shining light on that other 95%!In this conversation with Mike, he’ll give tips to newcomers, including some mistakes entrepreneurs often make in the early stages of their companies. Mike explains how you can pivot when an idea doesn’t pan out, and he’ll give his expertise on seed-stage fundraising as well as navigating the regulatory waters. Plus, more on his current work with DeVoro, including how he started working on problems related to peripheral thrombectomy.But first, a bit more on Mike’s medtech background:Prior to co-founding DeVoro Medical, Mike served as Chief Technical Officer and VP of Operations for Silk Road Medical. Mike has spent most of his professional career working for medical device start-ups, some of which include Target Therapeutics (acquired by Boston Scientific), BARRX Medical (acquired by Covidien), and Baxano (acquired by Trans1). In addition, Mike has co-founded and exited three other start-ups: TW Medical and GW Medical Neuro (both acquired by Stryker Corp) and CardioProlific (acquired by Philips). Mike graduated with a B.S. in Mechanical Engineering from the University of Delaware, holds a M.S. in Mechanical Engineering from the University of California, Davis, and is the co-inventor or primary inventor on over 130 issued U.S. patents.Before we jump into the conversation, I wanted to mention a few things:First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.I’ve never tried this before, so let me know what you think!Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. Lastly, here's the link to the full interview if you'd rather read it instead.

In this episode of Medsider Radio, we’re catching up with Bruce Shook, the President & CEO of Vesper Medical. Bruce is a medical device executive with more than 30 years of experience, and today, he’s sharing his insights with the Medsider community!In this conversation, we’ll discuss key aspects of running a medtech company, from the early design and fundraising stages through an eventual sale and exit. Bruce shares his expertise on raising start-up capital, designing and prototyping products, navigating the regulatory landscape, and managing reimbursement and coverage strategies. But first, here’s a bit about Bruce Shook’s background:Most recently, Bruce served as CEO of Intact Vascular, which sold to Philips. Prior to Intact Vascular and Vesper Medical, Bruce was co-founder, Director, President and CEO of Neuronetics, a publicly traded device company that markets a non-invasive brain stimulation technology for the treatment of depression.Previously, he was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders. Bruce also served as President of Abiomed, where he obtained a PMA for the first ventricular assist device. Bruce also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation.Bruce holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management. He also earned a B.S. degree in Chemical Engineering from Penn State University. Before we jump into the conversation, I wanted to mention a few things:First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.I’ve never tried this before, so let me know what you think!Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. Lastly, here's the link to the full interview if you'd rather read it instead.

In this episode of Medsider Radio, we’re talking with Mike Kujak, the President & CEO of Francis Medical.Mike breaks down Francis’ innovative new water vapor technologies, and provides some advice about developing the alpha & beta versions of a medtech product. We’ll also discuss how to navigate the early-stage regulatory environment, and hear Mike’s views on how best to plan & execute a clinical research strategy.Then we’ll discuss fundraising strategies and ask Mike what’s next for Francis Medical as the company plans for its second-generation development program. But first, a bit more on Mike's background...Most recently, Mike was the Chief Marketing Officer and Senior Vice President of International Markets for NxThera. Prior to that, he was the Vice President and General Manager of the Prostate Health business unit of American Medical Systems.Mike received his MBA from the University of St. Thomas and has a Bachelor of Science degree in physics and chemistry from the University of South Dakota.Before we jump into the conversation, I wanted to mention a few things:First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.I’ve never tried this before, so let me know what you think!Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. Lastly, here's the link to the full interview if you'd rather read it instead.

In this episode of Medsider Radio, we caught up with Sean Saint, the CEO of Companion Medical, which recently sold to Medtronic. Sean has more than 20 years of engineering experience in medical devices and various start-ups. Here are a few topics we covered in this interview:How Sean and his team at Companion Medical came up with the idea for the InPen.Sean's advice for raising money from medtech investors.Companion Medical's insurance and reimbursement strategy for the InPen.There's definitely a lot more that we cover in this discussion, but before we jump in, I wanted to mention a few things:First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. So here’s what’s different: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.I’ve never tried this before, so let me know what you think!Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. Lastly, here's the link to the full interview if you'd rather read it instead.

This interview brings us to the end of a throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.On this particular episode, I chatted with Rich Ferrari, Managing Director of De Novo Ventures, and one of the most well-known VCs in the Medtech space. Here are some of the points we covered:Novel ways to fund early-stage medical device companies.The metrics that are most important when it comes to early-stage versus late-stage medtech investing.Why does the FDA “runway” seem to get longer and longer over time?How Rich identifies and validates whether an idea is truly disruptive.Download the transcript here.

We're coming to the end of the throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.In this discussion with Sheila Heyer, President of Heyer Regulatory Solutions and former VP of Global Regulatory Affairs at Boston Scientific, we learn where medical device companies are missing the mark when it comes to the FDA approval process. Here are some of the things we chatted about:The three most important steps you can take right now to get your medical device approved faster.Quality submissions and solid relationships: the importance of honing these two concepts in order to enhance your regulatory approval process.The key characteristics that great medtech regulatory professionals all have in common.Check out the full interview here.

This interview is a continuation of a throwback mini-series that I’ve been releasing over the past few weeks with some of my favorite Medsider guests of all time.One of which is Lisa Suennen, who was then a Managing Member of Psilos Group, a healthcare-focused venture capital firm with approximately $600 million under management. Although this discussion is several years old and the audio quality isn’t the best, the insights Lisa provides are timeless. Here are some of the things we covered:What does Lisa think when the goal of physicians is to “dagger historical price lists."Why Lisa and her partners at the Psilos Group favor late-stage deals.Corporate venture capital arms: friend or foe? And if you’re an early-stage medical device company, what is the best way to get the attention of Lisa Suennen and her peers in the VC world?See more...

This interview is a continuation of a throwback mini-series I’ve been releasing over the past few weeks with some of my favorite Medsider guests.On this particular episode, I chatted with Randel Richner, a true expert in healthcare economics and reimbursement. At the time of this interview, she was with Neocure Group, a company she founded and later sold to Intralign. Although this discussion is several years old and the audio quality isn’t ideal, Randel's insights are timeless. Here are some of the things we covered:A case study of how Randel helped save a medical device company from severe reimbursement implications.Randel’s unique “orchestra score” philosophy and how it aids in streamlining reimbursement strategies.The importance of defining the difference between how hospitals get paid and how physicians get paid.And what Randel means by the statement “comparative effectiveness is a code word for cost-effectiveness”.See more...

This interview is part of a throwback mini-series to several years ago when I chatted with Kevin Bitterman, who at the time, was with Polaris Venture Partners. He’s now a partner with Atlas Venture, but the lessons you can glean from this discussion still hold true. Namely:What medtech venture capitalists like to see in a startup and how these early-stage medical device companies can best position themselves for success. What requirements would make for an attractive IPO opportunity?What questions should medtech startups have already answered before approaching a potential buyer?And in terms of a potential exit, what is more, important for a medical device startup – clinical data or commercial traction?See more...

This interview is part of a throwback mini-series from several years ago when I chatted with my good friend, Joe Hage. He’s the CEO of Medical Marcom and Chairman of the Medical Devices Group, a community of over 350,000 medical device members. In this entertaining interview, here are some of the things we talked about:How Joe, with a limited medical device industry background, helped Cardiac Science become a medtech marketing leader.Why Joe thinks search engine optimization (SEO) is among the most important elements for your marketing mix.How you can use editorials to demonstrate medical device industry leadership.And why sending prospects to your website homepage may not be the best idea.See more...

This interview is a throwback to several years ago when I chatted with Dr. David Albert about his incredible journey in bringing the AliveCor ECG app to market. Here are a few things we covered:The amazing story of how AliveCor’s iPhone app helped save a man’s life while on an airplane!The roller coaster ride Dr. Albert experienced in his pursuits to develop the ECG app.Five key lessons you can learn from Dr. Albert’s experiences. And his timeliness advice for ambitious doers, which includes the following: believe in your ideas don’t be afraid to swim against the stream.Click here to learn more.

On this episode of Medsider Radio, our guest is Travis Sessions, the Founder and Chief Executive Officer of Biomerics, a leading mid-market interventional device contract manufacturer. He's also a Managing Partner of Med Venture Holdings, a unique medtech growth equity investor. With over 20 years of business management experience, Travis has successfully built and grown multiple medical device technology companies during his career. He got his start professionally at Dow Chemical and has held management positions at Microsoft and Parker Hannifin Corporation. Travis has a B.S. in Chemical Engineering from Brigham Young University and a Master’s in Business Administration from the University of Michigan. Interview Highlights with Travis Sessions:Macro trends within the medtech market, including Travis’ thoughts on the future.Key differences between contract manufacturers (CMs) and large original equipment manufacturers (OEMs).Critical things that OEMs should look for when identifying and working with CMs.The origin story of Med Venture Holdings.What Travis looks for when vetting early-stage medtech ideas.Critical functions that need to be in place for a medical device startup to be acquired.Travis’ favorite book, the mentor he most admires, and the advice he’d give to his 30-year-old self.Learn more...

In this episode of Medsider Radio, our guest is Matthew Amsden, the Founder, and CEO of ProofPilot, a platform designed to help people design, launch and participate in clinical trials.ProofPilot’s mission statement revolves around making it incredibly easy to run scientifically-valid research studies. They’re dedicated to making research study participation accessible, interesting, and fun. In this discussion with Matthew, we chatted about the importance and feasibility of virtual clinical trials, how they can potentially become a revenue driver, the origin story of ProofPilot, and why their hybrid model is so popular.Interview Highlights with Matthew AmsdenWho is Matthew Amsden and where did the idea for ProofPilot begin? The importance of letting early customers try product iterations.How clinical studies can become a revenue driver. Various types of clinical trials and how they’re conducted on the ProofPilot platform.Risky and costly approaches to traditional clinical studies. The synergy between data, compliance, and incentives.How a virtual, hybrid model can solve problems when it comes to traditional clinical trials. Matthew’s favorite business book, the mentor he most admires, and the advice he’d give to his 30-year-old self.See more...

Over the last 20 years, Dr. Tej Singh has served as the Founder and Chief of Vascular Surgery for three large, multidisciplinary vascular programs in Silicon Valley. He has vast experience with renal failure and vascular access procedures and is acutely focused on his first company, Fist Assist Devices. Dr. Singh’s company is developing the first renal care wearable device for venous enlargement and dialysis enhancement. In this episode, Dr. Singh and I talk about the primary challenge that First Assist Devices is trying to solve, the origin story for their first product, his approach to mapping out clinical trial strategies, and much more. Interview Highlights with Dr. Tej SinghWho is Dr. Tej Singh and what is his background?What are Fist Assist Devices and what challenges are they trying to solve?The origin story for their first product and the critical inflection points for the company. How Dr. Singh evaluated the IP landscape for his first device. Dr. Singh’s approach to mapping out clinical trial strategies.How he navigated the insurance coverage and reimbursement landscape.His unique approach to strategic patience and why it’s crucial for medtech startups.Dr. Singh’s favorite book, the leader he most admires, and the advice he’d give to his 30-year-old self.See more...